Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 25 | 2025 | 187 | 6.550 |
Why?
|
| Immunotherapy, Adoptive | 30 | 2025 | 254 | 6.540 |
Why?
|
| Antigens, CD19 | 18 | 2025 | 69 | 3.160 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 12 | 2024 | 924 | 2.190 |
Why?
|
| Lymphoma, Mantle-Cell | 4 | 2024 | 39 | 1.840 |
Why?
|
| Lymphoma, Follicular | 5 | 2024 | 74 | 1.530 |
Why?
|
| Lymphoma, B-Cell | 6 | 2025 | 109 | 1.370 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2023 | 268 | 1.260 |
Why?
|
| Transplantation, Autologous | 7 | 2024 | 355 | 1.160 |
Why?
|
| Biological Products | 7 | 2025 | 171 | 1.070 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2025 | 419 | 1.000 |
Why?
|
| Standard of Care | 2 | 2024 | 68 | 0.890 |
Why?
|
| Oncologists | 1 | 2023 | 38 | 0.820 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2024 | 91 | 0.750 |
Why?
|
| Neoplasm Recurrence, Local | 14 | 2024 | 1398 | 0.730 |
Why?
|
| Humans | 65 | 2025 | 92331 | 0.700 |
Why?
|
| Blood Component Removal | 1 | 2020 | 27 | 0.690 |
Why?
|
| Jehovah's Witnesses | 1 | 2021 | 21 | 0.690 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2018 | 139 | 0.690 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2018 | 205 | 0.670 |
Why?
|
| Transplantation Conditioning | 3 | 2021 | 380 | 0.660 |
Why?
|
| Lymphoma | 3 | 2024 | 268 | 0.660 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 2555 | 0.640 |
Why?
|
| Retrospective Studies | 14 | 2025 | 9693 | 0.600 |
Why?
|
| Aged | 28 | 2025 | 19951 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2016 | 79 | 0.490 |
Why?
|
| Adult | 24 | 2025 | 27540 | 0.480 |
Why?
|
| Middle Aged | 25 | 2025 | 27043 | 0.470 |
Why?
|
| Graft vs Host Disease | 3 | 2023 | 366 | 0.450 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 47 | 0.430 |
Why?
|
| Hepatitis B | 1 | 2014 | 79 | 0.420 |
Why?
|
| Antineoplastic Agents | 4 | 2025 | 2365 | 0.420 |
Why?
|
| Rituximab | 5 | 2025 | 123 | 0.410 |
Why?
|
| Male | 29 | 2025 | 43922 | 0.410 |
Why?
|
| B-Lymphocytes | 1 | 2017 | 753 | 0.400 |
Why?
|
| T-Lymphocytes | 5 | 2025 | 1279 | 0.400 |
Why?
|
| Geriatric Assessment | 3 | 2024 | 186 | 0.380 |
Why?
|
| Female | 28 | 2025 | 47895 | 0.380 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1480 | 0.370 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2023 | 147 | 0.370 |
Why?
|
| Remission Induction | 5 | 2024 | 763 | 0.360 |
Why?
|
| Prognosis | 5 | 2025 | 3871 | 0.350 |
Why?
|
| Recurrence | 5 | 2025 | 1180 | 0.350 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2025 | 628 | 0.330 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2023 | 215 | 0.320 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2025 | 97 | 0.320 |
Why?
|
| Cell- and Tissue-Based Therapy | 4 | 2023 | 57 | 0.320 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 6917 | 0.300 |
Why?
|
| Treatment Outcome | 11 | 2025 | 8730 | 0.290 |
Why?
|
| Lymphoma, T-Cell | 2 | 2024 | 59 | 0.270 |
Why?
|
| Adolescent | 6 | 2025 | 9495 | 0.260 |
Why?
|
| Young Adult | 8 | 2025 | 6629 | 0.260 |
Why?
|
| Sarcopenia | 2 | 2016 | 19 | 0.250 |
Why?
|
| Killer Cells, Natural | 2 | 2025 | 277 | 0.250 |
Why?
|
| Sulfonamides | 2 | 2025 | 327 | 0.240 |
Why?
|
| Tissue Extracts | 1 | 2025 | 25 | 0.240 |
Why?
|
| Burkitt Lymphoma | 1 | 2025 | 33 | 0.240 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2025 | 12 | 0.240 |
Why?
|
| Adenine | 1 | 2025 | 89 | 0.230 |
Why?
|
| Antibodies, Bispecific | 1 | 2024 | 31 | 0.220 |
Why?
|
| Pyrazoles | 1 | 2025 | 154 | 0.220 |
Why?
|
| Oleic Acids | 1 | 2023 | 26 | 0.210 |
Why?
|
| Piperidines | 1 | 2025 | 164 | 0.210 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2023 | 11 | 0.210 |
Why?
|
| Candidiasis | 1 | 2023 | 37 | 0.210 |
Why?
|
| Survival Analysis | 3 | 2023 | 1512 | 0.200 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 142 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2025 | 378 | 0.190 |
Why?
|
| Veterans | 4 | 2016 | 89 | 0.190 |
Why?
|
| Tumor Burden | 1 | 2023 | 314 | 0.190 |
Why?
|
| Hodgkin Disease | 1 | 2023 | 170 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 184 | 0.180 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 117 | 0.180 |
Why?
|
| Maximum Tolerated Dose | 2 | 2024 | 268 | 0.170 |
Why?
|
| United States | 7 | 2023 | 7360 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2023 | 976 | 0.160 |
Why?
|
| Cladribine | 1 | 2019 | 35 | 0.160 |
Why?
|
| Carcinoma | 1 | 2023 | 438 | 0.160 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 61 | 0.160 |
Why?
|
| Hematologic Neoplasms | 1 | 2023 | 355 | 0.150 |
Why?
|
| Patient Selection | 2 | 2019 | 689 | 0.150 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 132 | 0.150 |
Why?
|
| Cell Differentiation | 1 | 2025 | 1606 | 0.150 |
Why?
|
| Neoplasms | 2 | 2023 | 3123 | 0.140 |
Why?
|
| Preoperative Care | 1 | 2019 | 405 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 341 | 0.130 |
Why?
|
| Patient Care Team | 1 | 2019 | 297 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2017 | 263 | 0.130 |
Why?
|
| Cyclophosphamide | 4 | 2021 | 304 | 0.130 |
Why?
|
| Obesity, Abdominal | 1 | 2016 | 8 | 0.130 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 342 | 0.130 |
Why?
|
| Body Composition | 1 | 2016 | 72 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2018 | 726 | 0.120 |
Why?
|
| Stem Cell Transplantation | 3 | 2021 | 190 | 0.120 |
Why?
|
| Survivors | 1 | 2016 | 199 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 329 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 315 | 0.110 |
Why?
|
| Anthracyclines | 1 | 2015 | 35 | 0.110 |
Why?
|
| Doxorubicin | 4 | 2016 | 296 | 0.110 |
Why?
|
| Febrile Neutropenia | 1 | 2014 | 16 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 807 | 0.110 |
Why?
|
| Venous Thromboembolism | 1 | 2016 | 165 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1150 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2025 | 3776 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2019 | 816 | 0.100 |
Why?
|
| Transplantation, Homologous | 3 | 2020 | 1015 | 0.100 |
Why?
|
| Heart Failure | 1 | 2023 | 1341 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1308 | 0.100 |
Why?
|
| Time Factors | 1 | 2021 | 5430 | 0.100 |
Why?
|
| Vincristine | 3 | 2016 | 109 | 0.090 |
Why?
|
| Prednisone | 3 | 2016 | 254 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2014 | 799 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2014 | 498 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2024 | 621 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2021 | 902 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1398 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2023 | 4474 | 0.070 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2025 | 51 | 0.060 |
Why?
|
| Receptors, CXCR4 | 1 | 2025 | 48 | 0.060 |
Why?
|
| Depsipeptides | 1 | 2024 | 29 | 0.060 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2024 | 5 | 0.060 |
Why?
|
| Vidarabine | 1 | 2025 | 144 | 0.060 |
Why?
|
| Dairy Products | 1 | 2023 | 11 | 0.050 |
Why?
|
| Red Meat | 1 | 2023 | 10 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2023 | 36 | 0.050 |
Why?
|
| Milk | 1 | 2023 | 55 | 0.050 |
Why?
|
| Deoxycytidine | 1 | 2024 | 212 | 0.050 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2023 | 68 | 0.050 |
Why?
|
| Sheep | 1 | 2023 | 249 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 109 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2023 | 225 | 0.050 |
Why?
|
| Cattle | 1 | 2023 | 381 | 0.050 |
Why?
|
| Troponin | 1 | 2023 | 27 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 280 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2024 | 347 | 0.050 |
Why?
|
| Melphalan | 1 | 2023 | 100 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2023 | 145 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 106 | 0.050 |
Why?
|
| C-Reactive Protein | 1 | 2023 | 205 | 0.050 |
Why?
|
| Mutation | 2 | 2025 | 4212 | 0.050 |
Why?
|
| Interleukin-6 | 1 | 2023 | 273 | 0.050 |
Why?
|
| Thiotepa | 1 | 2021 | 32 | 0.050 |
Why?
|
| Histiocytes | 1 | 2021 | 23 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 285 | 0.040 |
Why?
|
| Incidence | 2 | 2016 | 1661 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 149 | 0.040 |
Why?
|
| Risk Factors | 2 | 2024 | 5708 | 0.040 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Survival Rate | 1 | 2024 | 1926 | 0.040 |
Why?
|
| Chimerism | 1 | 2020 | 37 | 0.040 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 51 | 0.040 |
Why?
|
| Filgrastim | 1 | 2019 | 58 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 903 | 0.040 |
Why?
|
| Hydrazines | 1 | 2019 | 32 | 0.040 |
Why?
|
| Health Care Rationing | 1 | 2020 | 84 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 59 | 0.040 |
Why?
|
| Mice | 2 | 2023 | 12132 | 0.040 |
Why?
|
| Cytarabine | 1 | 2019 | 222 | 0.040 |
Why?
|
| Triazoles | 1 | 2019 | 107 | 0.040 |
Why?
|
| Animals | 3 | 2023 | 28060 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 539 | 0.030 |
Why?
|
| Palliative Care | 1 | 2019 | 262 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 290 | 0.030 |
Why?
|
| Steroids | 1 | 2018 | 173 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2020 | 531 | 0.030 |
Why?
|
| Abdominal Fat | 1 | 2016 | 13 | 0.030 |
Why?
|
| Biomarkers | 1 | 2023 | 1847 | 0.030 |
Why?
|
| Subcutaneous Fat | 1 | 2016 | 21 | 0.030 |
Why?
|
| Neutropenia | 1 | 2016 | 217 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2979 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 112 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 871 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1072 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2016 | 474 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1117 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 3375 | 0.020 |
Why?
|
| Hospitalization | 1 | 2016 | 925 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 2685 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 3514 | 0.020 |
Why?
|